EPS for RH (RH) Expected At $1.54; 2 Analysts Are Bullish PDL BioPharma, Inc. (PDLI) Last Week

February 16, 2018 - By Marguerite Chambers

Among 4 analysts covering PDL BioPharma (NASDAQ:PDLI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. PDL BioPharma had 9 analyst reports since October 16, 2015 according to SRatingsIntel. The stock has “Sector Perform” rating by RBC Capital Markets on Thursday, November 5. As per Thursday, October 26, the company rating was maintained by Cowen & Co. The stock has “Buy” rating by Piper Jaffray on Friday, November 3. The rating was maintained by RBC Capital Markets with “Sector Perform” on Friday, October 16. The company was maintained on Friday, August 4 by Cowen & Co. RBC Capital Markets maintained PDL BioPharma, Inc. (NASDAQ:PDLI) rating on Tuesday, February 2. RBC Capital Markets has “Sector Perform” rating and $5 target. The firm has “Sector Perform” rating given on Tuesday, February 23 by RBC Capital Markets. The rating was maintained by PiperJaffray on Thursday, December 22 with “Overweight”. See PDL BioPharma, Inc. (NASDAQ:PDLI) latest ratings:

03/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
26/10/2017 Broker: Cowen & Co Rating: Hold New Target: $3.0 Maintain

Analysts expect RH (NYSE:RH) to report $1.54 EPS on February, 22.They anticipate $0.86 EPS change or 126.47% from last quarter’s $0.68 EPS. RH’s profit would be $32.81 million giving it 14.93 P/E if the $1.54 EPS is correct. After having $1.04 EPS previously, RH’s analysts see 48.08% EPS growth. The stock decreased 0.61% or $0.56 during the last trading session, reaching $91.99. About 706,351 shares traded. RH (NYSE:RH) has risen 86.65% since February 16, 2017 and is uptrending. It has outperformed by 69.95% the S&P500.

Among 26 analysts covering Restoration Hardware Holdings (NYSE:RH), 7 have Buy rating, 1 Sell and 18 Hold. Therefore 27% are positive. Restoration Hardware Holdings had 95 analyst reports since July 31, 2015 according to SRatingsIntel. On Friday, June 23 the stock rating was upgraded by Deutsche Bank to “Buy”. Loop Capital initiated the shares of RH in report on Wednesday, January 4 with “Hold” rating. The company was upgraded on Friday, October 7 by Buckingham Research. Deutsche Bank maintained the shares of RH in report on Thursday, November 16 with “Buy” rating. The company was downgraded on Monday, July 17 by KeyBanc Capital Markets. The company was downgraded on Tuesday, February 7 by Buckingham Research. The firm has “Buy” rating given on Thursday, February 25 by Nomura. Deutsche Bank maintained RH (NYSE:RH) rating on Friday, June 2. Deutsche Bank has “Hold” rating and $4500 target. Oppenheimer maintained RH (NYSE:RH) on Friday, March 24 with “Hold” rating. The rating was maintained by Deutsche Bank with “Buy” on Thursday, February 25.

Investors sentiment increased to 1 in Q3 2017. Its up 0.67, from 0.33 in 2017Q2. It increased, as 1 investors sold RH shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 85,222 shares or 906.88% more from 8,464 shares in 2017Q2 were reported. Gemmer Asset Mngmt Limited Liability Company stated it has 64 shares. 8,200 are owned by First Commercial Bank Of Omaha. Eagle Asset Management owns 0.03% invested in RH (NYSE:RH) for 76,958 shares.

Since December 13, 2017, it had 0 insider purchases, and 1 insider sale for $2.19 million activity. 22,000 shares valued at $2.19 million were sold by Boone Karen on Wednesday, December 13.

RH, together with its subsidiaries, operates as a retailer in the home furnishings market. The company has market cap of $1.96 billion. The firm offers products in various categories, including furniture, lighting, textiles, bathware, d??cor, outdoor and garden, tableware, and child and teen furnishings. It has a 273.78 P/E ratio. It provides its products through its retail galleries and Source Books, as well as online through rh.com, rhmodern.com, restorationhardware.com, rhbabyandchild.com, rhteen.com, and waterworks.com Websites.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $382.76 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It has a 5.04 P/E ratio. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: